IL13RA2 and prostate carcinoma: In our study, IL13Rα2 was highly expressed in castration‐resistant PDX tumors compared with castration‐sensitive tumors, indicating that the IL13Rα2 has a potential to predict the castration‐sensitivity of prostate cancer.